Biocon, a leading biotechnology company, witnessed a rise in share price on Tuesday after the delay in Pfizer's Herceptin biosimilar that will benefit Biocon/Mylan. The company already has USFDA approval for this biosimilar.

Pfizer has said that USFDA's query is not related to manufacturing but related to the technical details. Pfizer has not indicated exact nature of the details as well as the timeline for resubmission of its application.

Shares of the company are trading at Rs 654.20, up Rs 19.4, or 3.06% at the Bombay Stock Exchange (BSE) on Tuesday at 10:19 a.m.

The scrip has touched an intra-day high of Rs 656.80 and low of Rs 638.00. The total volume of shares traded at the BSE is 205,074.